Vitestro Revolutionizes Blood Draws with $22M Funding Boost

Vitestro, the autonomous blood drawing company, secures $22 million to accelerate commercialization of its innovative robotic device. The funding round, led by Sonder Capital and NYBC Ventures, aims to drive European expansion and U.S. market entry. Vitestro's blend of AI, imaging technology, and robotics enhances patient and clinician satisfaction by minimizing manual intervention. The company's device, currently in pre-order for European hospitals, aims to alleviate workloads and enhance patient experiences. With plans for CE approval by 2024, Vitestro anticipates rapid deployment. The company's A.D.O.P.T. trial, the largest assessment of autonomous blood drawing devices globally, aims to pioneer additional product enhancements. Vitestro's CEO, Toon Overbeeke, expresses excitement for global impact and expansion. Vitestro's device, combining AI, imaging, and robotics, offers accurate and autonomous blood draws, reducing manual handling and improving patient experiences. The company's $50 million total funding will drive commercial expansion in Europe and U.S. markets. Vitestro's device, utilizing AI and robotics, provides accurate and autonomous blood draws, reducing manual handling and improving patient experiences. The company's plans for European commercialization and U.S. market entry aim to transform blood draws globally.